Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (171-180 of 367) with videos related to

Pageof 37
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2012
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysisAdrianus J de Langen, Andrew Vincent, Linda M Velasquez, et al.
Plos One|November 20, 2019
Correction: Clonality analysis of pulmonary tumors by genome-wide copy number profilingJulien P L Vincenten, Hendrik F van Essen, Birgit I Lissenberg-Witte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2012
Benefit of a second opinion for lung cancer: no recurrent disease, but infectionRomane M Schook, Schook M Romane, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancerRoderick H J Breuer, Peter J F Snijders, Thomas G Sutedja, et al.
Clinical Lung Cancer|March 29, 2017
Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the NetherlandsNaomi van der Linden, Mathilda L Bongers, Veerle M H Coupé, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical TrialsBarend J Sikkema, Sara J Baart, Marthe S Paats, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutationAnne-Marie C Dingemans, Wouter W Mellema, Harry J M Groen, et al.
Plos One|October 17, 2019
Clonality analysis of pulmonary tumors by genome-wide copy number profilingJulien P L Vincenten, Hendrik F van Essen, Birgit I Lissenberg-Witte, et al.
Journal of Cancer Research and Clinical Oncology|March 7, 2015
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancerLonneke Timmers, Christel C L M Boons, J Moes-Ten Hove, et al.
Pageof 37

Showing results (171-180 of 367) with videos related to

Sort By:
Pageof 37
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2012
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysisAdrianus J de Langen, Andrew Vincent, Linda M Velasquez, et al.
Plos One|November 20, 2019
Correction: Clonality analysis of pulmonary tumors by genome-wide copy number profilingJulien P L Vincenten, Hendrik F van Essen, Birgit I Lissenberg-Witte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2012
Benefit of a second opinion for lung cancer: no recurrent disease, but infectionRomane M Schook, Schook M Romane, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancerRoderick H J Breuer, Peter J F Snijders, Thomas G Sutedja, et al.
Clinical Lung Cancer|March 29, 2017
Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the NetherlandsNaomi van der Linden, Mathilda L Bongers, Veerle M H Coupé, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical TrialsBarend J Sikkema, Sara J Baart, Marthe S Paats, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutationAnne-Marie C Dingemans, Wouter W Mellema, Harry J M Groen, et al.
Plos One|October 17, 2019
Clonality analysis of pulmonary tumors by genome-wide copy number profilingJulien P L Vincenten, Hendrik F van Essen, Birgit I Lissenberg-Witte, et al.
Journal of Cancer Research and Clinical Oncology|March 7, 2015
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancerLonneke Timmers, Christel C L M Boons, J Moes-Ten Hove, et al.
Pageof 37